Kyung Chu on Treating Different Subtypes of the KRAS Mutation

Video

Kyung Chu, RN, NYU Langone Perlmutter Cancer Center, discusses treating patients with different subtypes of KRAS mutation.

Kyung Chu, RN, NYU Langone Perlmutter Cancer Center, discusses treating patients with different subtypes of KRAS mutation.

Typically, EGFR inhibitors are used in lung and colon cancer to treat patients with KRAS mutations. However, this therapy has mixed clinical outcomes for the patients, varying by their mutation subtype. Chu emphasizes that nurses and doctors must use the EGFR inhibitors wisely, and consider the patient’s subtype when deciding on a treatment plan.

Recent Videos
Photo of Jamie Carroll, APRN, CNP, MSN, from a video call with an Oncology Nursing News branded border around the frame
5 experts in this video
Image of Kayle Freeman, DNP, APRN, FNP-C, in a video call with an Oncology Nursing News border around the frame
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of Pattie Jakel, MN, RN, AOCN, in front of a blue watercolor Oncology Nursing News backdrop
Related Content
Anatomical rendering of a person's lungs

Pembrolizumab Combo May Benefit Elderly Metastatic NSCLC Cohort

Russ Conroy
March 15th 2025
Article

A phase 2 trial found that pembrolizumab plus pemetrexed met its objective response rate primary end point.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

Lindsay Fischer
November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

green background with dark blue text indicating FDA and green text indicating approved with a checkmark

FDA Approves Tislelizumab Combo for Advanced ESCC

Ashling Wahner;Kristi Rosa
March 4th 2025
Article

The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with PD-L1-positive, unresectable or metastatic esophageal squamous cell carcinoma.

The Vitals

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Lindsay Fischer
October 31st 2023
Podcast

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Blue image of a person with the esophagus and stomach highlighted in orange

Perioperative FLOT Improves Survival in Resectable Esophageal Carcinoma

Bridget Hoyt
February 24th 2025
Article

Perioperative chemotherapy improved survival compared with preoperative chemoradiotherapy in managing esophageal cancer.

Illustration of a clipboard with the word "Guidelines" on top of the page, followed by a check list

NCCN Guideline Updates on ctDNA Stance in MCC and Colon, Rectal Cancer

Kyle Doherty
February 22nd 2025
Article

The NCCN updated its guidelines to clarify the role of ctDNA as a biomarker for recurrence risk in colon and rectal cancer and for disease monitoring in Merkel cell carcinoma.